BridgeBio Pharma, Inc. — Director's Dealing 2020

Jun 5, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-06-02

Reporting Person: Cook Jennifer E. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-02	Stock Option (right to buy)	$29.00	A	112422	Acquired	2030-06-01	Common Stock (112422)	Direct

Footnotes

F1: The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.